Enterosgel

Polymethylsiloxane polyhydrate (PMSPH), or methylsilicic acid hydrogel (brand name — Enterosgel), is an enterosorbent used for binding and removing various toxic substances, infectious agents and metabolites from the gastrointestinal tract. It is available in the form of a homogeneous pasty mass of white or almost white colour, odorless and tasteless.

History

This product was synthesized in the late 1970s - early 1980s in the USSR by I. B. Slinyakova and I. М. Samodumova of L. B. Pisarzhevskiy Institute of Physical Chemistry (Kyiv), where the theoretical foundations for the formation of the porous structure of organosilicon adsorbents with an adjustable porous structure and a pre-defined chemical nature of the surface were established; there were also efforts to synthesize organosilicon adsorbents, namely porous polymers polyorganosiloxanes. Industrial production of the preparation began in early 1991. In 1994, a medicinal drug with methylsilicic acid hydrogel as the active ingredient, marketed under the brand name Enterosgel, was registered in Ukraine and Russia, and active sales of the new product began.

Currently, the product is already available in 40 countries.

The study of the use of the preparation was conducted in cooperation with the Medical Service of Krasnoznamennyi Kiev Military District (Medical Service Colonel Professor F. G. Novikov, Medical Service Colonel N. P. Bezlyuda). Since, many clinical trials investigating the preparation have been conducted by Ukrainian and Russian companies in the CIS.

A large-scale study of its effect was conducted in the United Kingdom between 2019 and 2022. It established a proven base of effectiveness of the preparation in the treatment of irritable bowel syndrome with diarrhea, help in relieving bloating, abdominal pain and urgency.

The preparation is registered in Russia and the CIS countries as a medicinal drug, and in the countries of the European Union, Serbia, New Zealand, Africa as a medical device, since the product is not absorbed into the bloodstream and acts as an adsorbent only in the gastrointestinal tract, it fits the relevant definition according to the Classification of the European Commission.

The medical device Enterosgel is produced in a modern high-tech factory in Jeseník, Czech Republic, from where it is exported to all countries of the world, except Russia and the CIS countries. This region supplies production in Russia, where a factory is situated in the city of Dankov.

Structure

Enterosgel (PMSPH) or methylsilicic acid hydrogel is a polymeric gelatinous organosilicon compound. The gel is dispersed in water to a particle size of no more than 300 microns. The preparation is a suspension which is taken orally

Microstructure

Electron microscopic studies have shown that its gel-forming matrix has a globular structure and consists of an ensemble of fused globules. These globules, bound together by siloxane bonds, form pores. The pores are the spaces between the globules. They are filled with water. Pore size is restricted. The presence of methyl groups on the surface ensures its hydrophobic properties. Enterosgel particles (PMSPH) tend to form a continuous network in a suspension to reduce the interaction of hydrophobic SiCH₃ with water. These particles can be viewed as two-dimensional sheets rather than three-dimensional solid particles. Aqueous suspensions of polymethylsiloxane polyhydrate are characterized by high viscosity.

Mechanism of action

The physical and chemical characteristics of Enterosgel define its absorptive and protective properties:

# The solid porous structure of the gel-forming matrix determines absorption capacity by the molecular adsorption mechanism and allows predominantly adsorbing medium molecular weight toxic substances and metabolites (e.g. bilirubin and products of protein breakdown).
# Due to its gel-like consistency:
#* it absorbs high-molecular-weight toxic substances by the mechanism of co-precipitation in the gel (e.g. bacterial toxins); Nikolaev, 2010, с. 45.
#* it shows protective properties — its elastic gel-like particles form a layer on the surface of mucous membranes. This layer protects mucous membranes from various damaging factors, and its protective properties are manifested universally — in the intestine, and on the surface of the mucous membranes of other organs.

It absorbs toxic substances produced in the gastrointestinal tract, as well as toxic substances entering the gastrointestinal tract from the environment (e.g., ethyl alcohol). It also prevents reabsorption of toxic substances and metabolites excreted into the intestinal lumen from the blood, as well as getting into the intestine with bile.

In an ''in vitro'' experiment, it reduced the production of staphylococcal enterotoxin and inhibited the growth of ''Staphylococcus aureus''.

It reduced malonic dialdehyde formation and increased integral antiradical activity in toxic liver damage ''in vivo''.

Due to adsorption in the gastrointestinal tract, it helps reduce blood sugar and glycated hemoglobin levels, eliminate lipid distress syndrome, including diabetic dyslipidemia, improves energy processes in liver tissues in experimental diabetes.

Enterosgel (PMSPH) firmly binds and excretes pathogenic bacteria and rotaviruses.

Highly viscous PMSPH particles cover mucosal areas and protect them from the damaging effects of bacterial toxins and various active chemical compounds (e.g., deconjugated bile salts that damage the mucosa of the gastrointestinal tract).

Enterosgel has a pronounced ability to absorb lipopolysaccharide molecules. Large molecules of lipopolysaccharide are co-precipitated in the gel and excreted from the body. A daily dose of PMSPH (Enterosgel paste) binds 410 mg of LPS.

Lipopolysaccharide (LPS), which has extremely high biological activity, can be found in the outer wall of all Gram-negative bacteria and is released only when the bacterium is destroyed, and is also known as endotoxin (the prefix endo- means inside, inside the bacterium). The distal section of the intestine is the main reservoir of Gram-negative microflora and lipopolysaccharides. Normally, only a small amount of endotoxin enters the bloodstream because the intestinal wall works as a barrier and limits the inflow of endotoxin into the bloodstream. Most (94%) of the endotoxin entering the bloodstream undergoes detoxification in the liver. However, a small amount of endotoxin bypasses the liver and enters the systemic bloodstream, maintaining physiological concentration of endotoxin in the blood (physiological endotoxinemia).

The process of endotoxin entering the bloodstream can be intensified by various lesions of the intestinal mucosa and by dysbacteriosis, which is accompanied by translocation of bacteria and products of their life activity into the small intestine and as a result of antibiotic-induced death of Gram-negative microflora and the release of large amounts of endotoxin. It should be particularly emphasized that various stressful situations (severe seizures, burns, trauma, etc.) cause damage to the mucous membrane of the gastrointestinal tract. This damage occurs due to redistribution of energy and structural resources of the body, i.e. transfer from systems not involved in adaptation to the stress factor to systems providing adaptation. An increase in the concentration of endotoxin in the blood exceeding the physiological norm leads to a pathological condition known as endotoxin aggression. Endotoxin aggression is a universal factor in the pathogenesis of human diseases, the development of which is caused by an excess of endotoxin entering the general bloodstream and a lack of endotoxin-binding systems. Excess endotoxin causes endothelial damage in the microcirculatory vessels of the intestinal mucosa and leads to the development of mucosal ischemia. This, in turn, causes further damage to the mucosa and a weakening of the intestinal barrier.

Reduction of endotoxin back to physiological levels in the blood prevents damage to the vascular wall and restores impaired blood supply to the intestinal mucosa and eliminates mucosal ischemia. The latter, in turn, contributes to its regeneration and restoration of the barrier function of the intestinal mucosa. The positive effect of using Enterosgel (PMSPH) is primarily aimed at preserving/restoring the intestinal barrier, restoring the physiological level of endotoxin and breaking the vicious circle caused by damage to the mucous membrane. This inhibits the development of endotoxin aggression.

''Notes''

Figure 1: ''As a result of insufficiency of the intestinal barrier, the concentration of LPS in the blood flow of the mucous membrane increases, which leads to disruption of microcirculation and ischemia of the mucous membrane, its damage and further development of intestinal barrier insufficiency. Endotoxin aggression develops.''

Figure 2: ''The use of Enterosgel (PMS PH) reverses the course of events: the level of LPS decreases, microcirculation processes in the intestinal mucosa are restored, and so are the intestinal mucosa and the functions of the intestinal barrier (more)''.

Effects on the human

PMSPH is not absorbed in the gastrointestinal tract and is excreted in an unchanged form within 12 hours.

It binds and removes endogenous and exogenous toxic substances of various nature, including bacteria and bacterial toxins, antigens, food allergens, drugs and poisons, salts of heavy metals, alcohol, from the lumen of the gastrointestinal tract. It also sorbs some metabolic products of metabolism, including excess bilirubin, urea, cholesterol, and lipid complexes, as well as metabolites responsible for the development of endogenous intoxication.

Indications for use

Enterosgel (PMSPH) is used in adults and children for the treatment and prevention of acute and chronic intoxications of various etiology (e.g. alcohol intoxication, botulism, mushroom poisoning) including viral and bacterial ones.

The efficacy and safety of the drug for registered indications is continuously monitored as part of routine pharmacovigilance according to Eurasian Union and European Union (GVP) requirements.

The results of randomized clinical trials, including double-blind placebo-controlled trials, in Russia, the CIS, Europe, etc., are evaluated.

In the 2022 RELIEVE IBS-D randomized double blinded placebo controlled study was published in the GUT journal. The study confirmed safety and efficacy in treatment of Irritable bowel syndrome with diarrhea. Enterosgel was effective in relieving the abdominal pain, diarrhoea, bloating and urgency.

Enterosgel is included in the clinical guidelines of state and non-state medical organizations of healthcare professionals in the CIS countries.

For example in a study in Croatia, it was used as concomitant therapy in women receiving radiotherapy and chemotherapy for pelvic cancer, and the results showed that it had an effect on the reduction of intoxication symptoms (nausea, vomiting, etc.).

It has been successfully used for hyperbilirubinemia (viral hepatitis,) including for hemolytic disease in newborns.

Also in chronic renal insufficiency (hyperazotemia). It has proved itself in the treatment of allergic diseases such as atopic dermatitis. When indicated, it is used to treat gastroenterological disorders. Thus, it is recommended for the treatment of acute and chronic diarrhea, dysbiosis including diarrhea of non-infectious origin, including for the treatment of irritable bowel syndrome with diarrhea. In acute and chronic infectious and inflammatory diseases, it is used in obstetrics and gynecology, since it is approved for use in pregnant women and children from birth.''Манухин И.Б., Крапошина Т.П., Керимова С.П., Хованов А.В.'
Энтеросорбция в лечении пациенток с хроническим эндометритом
''Акушерство и гинекология''. Bionica Media (2021). Дата обращения: 12 января 2022

22 января 2021 года.

Notes

Bibliography

*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
{{Refend

Drugs acting on the gastrointestinal system and metabolism
Soviet inventions
Ukrainian inventions
Drugs in the Soviet Union
Silicones
Siloxanes